Business as usual has not been the mantra for companies developing Covid-19 vaccines and drugs.
Instead, biopharma companies and their partners pursued various transformational approaches to get vaccines and treatments to market at unprecedented speeds. These included adaptive trials, master protocols, real-world evidence, and other approaches powered by advanced statistical techniques, data science, and analytics using curated datasets.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
.jpg?itok=F5fb_yNp)
